Nevro Corp
12
1
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
85.7%
-0.8% vs industry average
8%
1 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
Role: lead
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
Role: lead
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
Role: lead
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Role: lead
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
Role: lead
Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1
Role: lead
SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease
Role: collaborator
Nerve Root Block in Spasticity
Role: collaborator
HF10 Treatment of Chronic Knee Pain
Role: lead
SCS for the Treatment Of Chronic Pain of the Upper Extremities
Role: lead
Clinical Trial of the Senza™ SCS System in the Treatment of Chronic Upper Limb and Neck Pain
Role: lead
Comparison of Senza to Commercial Spinal Cord Stimulation for the Treatment of Chronic Pain
Role: lead
All 12 trials loaded